α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid receptor activation protects against phencyclidine-induced caspase-3 activity by activating voltage-gated calcium channels

Journal of Neuroscience Research

Volumn 92, Issue 12, 2014, Pages 1785-1791

  Timpe, Jennifer M ^a   Wang, Cheng Z ^a   Kim, Jisoo ^a   Johnson, Kenneth M ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

AMPA; Calcium; Neurotoxicity; NMDA; Phencyclidine

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CADMIUM CHLORIDE; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL P TYPE; CALCIUM CHANNEL Q TYPE; CASPASE 3; K 252A; NIFEDIPINE; OMEGA CONOTOXIN; PHENCYCLIDINE; VOLTAGE GATED CALCIUM CHANNEL; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; AMINO ACID RECEPTOR AFFECTING AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA FRAGMENTATION; ENZYME ACTIVATION; ENZYME ACTIVITY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN CORTEX; CORPUS STRIATUM; DRUG EFFECTS; IN VITRO STUDY; METABOLISM; NEWBORN; ORGAN CULTURE TECHNIQUE; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; TIME;

6-CYANO-7-NITROQUINOXALINE-2,3-DIONE; ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CASPASE 3; CEREBRAL CORTEX; CORPUS STRIATUM; EXCITATORY AMINO ACID AGENTS; IN VITRO TECHNIQUES; ORGAN CULTURE TECHNIQUES; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84919578724     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23446     Document Type: Article

References (36)

1. Anastasio NC, Johnson KM. 2008. Atypical antischizophrenic drugs prevent changes in cortical N-methyl-D-aspartate receptors and behavior following sub-chronic phencyclidine administration in developing rat pups. Pharmacol Biochem Behav 90:569-577.
2. Beasley CL, Reynolds GP. 1997. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr Res 24:349-355.
3. Burnashev N, Monyer H, Seeburg PH, Sakmann B. 1992. Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit. Neuron 8:189-198.
4. Chen H, Wang CZ, Ding C, Wild C, Copits B, Swanson GT, Johnson KM, Zhou J. 2013. A combined bioinformatics and chemoinformatics approach for developing asymmetric bivalent AMPA receptor positive allosteric modulators as neuroprotective agents. Chem Med Chem 8:226-230.
5. Cohen P, Goedert M. 2004. GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 3:479-487.
6. Coyle JT. 2006. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 26:365-384.
7. Damgaard T, Larsen DB, Hansen SL, Grayson B, Neill JC, Plath N. 2010. Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats. Behav Brain Res 207:144-150.
8. Deutsch SI, Rosse RB, Schwartz BL, Mastropaolo J. 2001. A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin Neuropharmacol 24:43-49.
9. Farber NB, Wozniak DF, Price MT, Labruyere J, Huss J, St Peter H, Olney JW. 1995. Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia? Biol Psychiatry 38:788-796.
10. 2+ permeability of AMPA receptors in principal neurons and interneurons in rat CNS. Neuron 15:193-204.
11. Hanson JE, Smith Y. 2002. Subcellular distribution of high-voltage-activated calcium channel subtypes in rat globus pallidus neurons. J Comp Neurol 442:89-98.
12. Hume RI, Dingledine R, Heinemann SF. 1991. Identification of a site in glutamate receptor subunits that controls calcium permeability. Science 253:1028-1031.
13. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vockler J, Dikranian K, Tenkova TI, Stefovska V, Turski L, Olney JW. 1999. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283:70-74.
14. Ikonomidou C, Bittigau P, Ishimaru MJ, Wozniak DF, Koch C, Genz K, Price MT, Stefovska V, Horster F, Tenkova T, Dikranian K, Olney JW. 2000. Ethanol-induced apoptotic neurodegeneration and fetal alcohol syndrome. Science 287:1056-1060.
15. Javitt DC. 2004. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9:984-997, 979.
16. Jentsch JD, Roth RH. 1999. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-225.
17. Jope RS, Roh MS. 2006. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets 7:1421-1434.
18. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS. 1994. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214.
19. Lei G, Xia Y, Johnson KM. 2008. The role of Akt-GSK-3beta signaling and synaptic strength in phencyclidine-induced neurodegeneration. Neuropsychopharmacology 33:1343-1353.
20. Lei G, Anastasio NC, Fu Y, Neugebauer V, Johnson KM. 2009. Activation of dopamine D1 receptors blocks phencyclidine-induced neurotoxicity by enhancing N-methyl-D-aspartate receptor-mediated synaptic strength. J Neurochem 109:1017-1030.
21. Marino MJ, Conn PJ. 2002. Direct and indirect modulation of the N-methyl D-aspartate receptor. Curr Drug Targets CNS Neurol Disord 1:1-16.
22. McDonald JW, Johnston MV. 1993. Excitatory amino acid neurotoxicity in the developing brain. NIDA Res Monogr 133:185-205.
23. Moghaddam B, Jackson ME. 2003. Glutamatergic animal models of schizophrenia. Ann N Y Acad Sci 1003:131-137.
24. Monyer H, Seeburg PH, Wisden W. 1991. Glutamate-operated channels: developmentally early and mature forms arise by alternative splicing. Neuron 6:799-810.
25. Noraberg J, Kristensen BW, Zimmer J. 1999. Markers for neuronal degeneration in organotypic slice cultures. Brain Res Brain Res Protoc 3:278-290.
26. Olney JW, Farber NB. 1995. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007.
27. Olney JW, Labruyere J, Price MT. 1989. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244:1360-1362.
28. Song L, De Sarno P, Jope RS. 2002. Central role of glycogen synthase kinase-3beta in endoplasmic reticulum stress-induced caspase-3 activation. J Biol Chem 277:44701-44708.
29. Timmermann DB, Westenbroek RE, Schousboe A, Catterall WA. 2002. Distribution of high-voltage-activated calcium channels in cultured gamma-aminobutyric acidergic neurons from mouse cerebral cortex. J Neurosci Res 67:48-61.
30. Wang C, McInnis J, Ross-Sanchez M, Shinnick-Gallagher P, Wiley JL, Johnson KM. 2001. Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience 107:535-550.
31. Wang CZ, Johnson KM. 2007. The role of caspase-3 activation in phencyclidine-induced neuronal death in postnatal rats. Neuropsychopharmacology 32:1178-1194.
32. Wang CZ, Yang SF, Xia Y, Johnson KM. 2008. Postnatal phencyclidine administration selectively reduces adult cortical parvalbumin-containing interneurons. Neuropsychopharmacology 33:2442-2455.
33. Wang HX, Gao WJ. 2012. Prolonged exposure to NMDAR antagonist induces cell-type specific changes of glutamatergic receptors in rat prefrontal cortex. Neuropharmacology 62:1808-1822.
34. Xia Y, Wang CZ, Liu J, Anastasio NC, Johnson KM. 2008. Lithium protection of phencyclidine-induced neurotoxicity in developing brain: the role of phosphatidylinositol-3 kinase/Akt and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling pathways. J Pharmacol Exp Ther 326:838-848.
35. Xia Y, Wang CZ, Liu J, Anastasio NC, Johnson KM. 2010. Brain-derived neurotrophic factor prevents phencyclidine-induced apoptosis in developing brain by parallel activation of both the ERK and PI-3K/Akt pathways. Neuropharmacology 58:330-336.
36. Zhang Z, Sun J, Reynolds GP. 2002. A selective reduction in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia patients. Chin Med J 115:819-823.